Ann: ITL Launches more Blood Sector Products, page-11

Some relevant commentary at last, on the need to be committed to the long term value of the IP held by this company. Long term investing is not for the faint hearted and requires a straight forward commitment to the core propositions of the products and their market sector. BioTech is a niche frontier yet it is far less cryptic and fashionable than other tradable IP commodities. It would be a mistake to underestimate the science ethos behind this company.